


Company Overview

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

Our portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Gilead was founded in 1987 in Foster City, California. Since then, we have grown to become one of the world's largest biopharmaceutical companies, with nearly 9,000 employees across six continents.

\$ in millions **Total Product Sales**



*Other comprised primarily of Letairis, Ranexa, Ambisome, Zydelig, Cayston and Lexiscan.


COMMERCIAL PORTFOLIO

| HIV | LIVER | ONCOLOGY | RESPIRATORY |
|---|---|---|--|
| Genvoya® elvitegravir /cobicistat / emtricitabine/tenofovir alafenamide Stribild® elvitegravir /cobicistat/ emtricitabine/tenofovir disoproxil fumarate Odefsey® rilpivirine/emtricitabine/ tenofovir alafenamide Complera® emtricitabine/rilpivirine/ tenofovir disoproxil fumarate Atripla® efavirenz/emtricitabine/ tenofovir disoproxil fumarate Tybost® cobicistat | Descovy® emtricitabine / tenofovir alafenamide Truvada® emtricitabine/tenofovir disoproxil fumarate Viread® tenofovir disoproxil fumarate Emtriva® emtricitabine Vitekta® elvitegravir Hepsera® adefovir dipivoxil for Chronic hepatitis B | Epclusa® sofosbuvir/velpatasvir for Chronic hepatitis C Harvoni® ledipasvir/sofosbuvir for Chronic hepatitis C Sovaldi® sofosbuvir for Chronic hepatitis C Vemlidy® tenofovir alafenamide for Chronic hepatitis B Viread® tenofovir disoproxil fumarate for Chronic hepatitis B Ranexa® ranolazine for Chronic angina Lexiscan® regadenoson injection for Coronary vasodilatation <small>Images shown do not represent actual size.</small> | Cayston® aztreonam for Cystic fibrosis Tamiflu® oseltamivir phosphate for Influenza A and B OTHER Ambisome® amphotericin B liposome for Fungal infections Macugen® pegaptanib sodium for Macular degeneration |

Images shown do not represent actual size.

First Quarter 2017 Financial Highlights

- ▶ Total revenues for the first quarter of 2017 decreased 17% to \$6.5 billion from \$7.8 billion for the first quarter of 2016.
- ▶ Non-GAAP net income for the first quarter of 2017, which excludes amounts related to acquisition, stock-based compensation, and other was \$2.9 billion, or \$2.23 per diluted share compared to \$4.3 billion, or \$3.03 per diluted share
- ▶ Product sales decreased 17% to \$6.4 billion for the first quarter of 2017 compared to \$7.7 billion for the first quarter
- ▶ As of March 31, 2017, Gilead had \$34.0 billion of cash, cash equivalents and marketable securities compared to \$32.4 billion as of December 31, 2016.
- ▶ During the first quarter of 2017, Gilead generated \$2.9 billion in operating cash flow.



Senior Leadership

John F. Milligan, PhD
 President and Chief Executive Officer

John C. Martin, PhD
 Executive Chairman

Gregg H. Alton
 Executive Vice President,
 Corporate and Medical Affairs

Norbert W. Bischofberger, PhD
 Executive Vice President,
 Research and Development and
 Chief Scientific Officer

Andrew Cheng, MD, PhD
 Executive Vice President, Clinical
 Research & Development Operations

William A. Lee, PhD
 Executive Vice President, Research

John McHutchison, MD
 Executive Vice President,
 Clinical Research

Jim Meyers
 Executive Vice President,
 Worldwide Commercial Operations

Brett Pletcher
 Executive Vice President, General
 Counsel and Chief Compliance Officer

Martin Silverstein, MD
 Executive Vice President, Strategy

Robin L. Washington
 Executive Vice President and
 Chief Financial Officer

Katie L. Watson
 Executive Vice President,
 Human Resources

Taiyin Yang, PhD
 Executive Vice President,
 Pharmaceutical Dev. & Manufacturing

Kevin Young CBE
 Chief Operating Officer

Analyst Coverage

Argus Research Company
 David Toung

Atlantic Equities
 Steve Chesney

Bank of America Merrill Lynch
 Ying Huang

Barclays
 Geoff Meacham

BMO
 Ian Somaiya

Citi
 Robyn Karnauskas

Cowen & Company
 Phil Nadeau, PhD

Credit Suisse
 Alethia Young

Evercore ISI
 Mark Schoenebaum

Goldman Sachs & Co.
 Terence Flynn, PhD

Guggenheim Securities
 Tony Butler

JPMorgan
 Cory Kasimov

Leerink Partners
 Geoff Porges, MBBS

Maxim Group
 Jason Kolbert

Mizuho
 Salim Syed

Morgan Stanley
 Matthew Harrison

Morningstar
 Karen Andersen, CFA

Needham
 Alan Carr, PhD

Piper Jaffray & Co.
 Joshua Schimmer, MD

Robert W. Baird
 Brian Skorney

Standard and Poors
 Steven Silver


Stifel
 Katherine Breedis

UBS
 Carter Gould

Wells Fargo
 Jim Birchenough

William Blair & Company
 John Sonnier

STOCK CHART



CONTACT INFORMATION

Gilead Sciences, Inc.
 Investor Relations
 333 Lakeside Dr.
 Foster City, CA 94404
 Phone (800) 445-3235
 Fax (650) 522-5853
 investor_relations@gilead.com
 www.gilead.com

*As of 3/31/2017

